Company ProfilePremium

Cube&Company Co., Ltd.

Company Profile Analysis

Ticker: 043090.KQ주식회사 더테크놀로지

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cube&Company Co., Ltd. - Company showcase

Year Founded & Workforce

1987

34 Employees

Cube&Company Co., Ltd. logo

Cube&Company Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cube&Company Co., Ltd. Overview

FieldDetailSource
Current legal name주식회사 더테크놀로지 / The Technology Co., Ltd.KIND quarterly report (Q3 FY2025), Edaily 29 Mar 2024
Name requested in briefCube&Company Co., Ltd. (큐브앤컴퍼니), used 24 Oct 2019 – Sep 2021Hankyung / Edaily / Newspim, 24 Oct 2019
Former names (chronological)Korea Fermentation Co. (한국발효기㈜) → Co-Biotech (코바이오텍㈜, Apr 2000) → Pharmswell Bio (팜스웰바이오, May 2008) → Cube&Company (Oct 2019) → Hanju Chemical & Holdings (한주케미칼앤홀딩스, Sep 2021) → Hanchang Biotech (한창바이오텍, Nov 2021) → Exergy21 (엑서지21, Sep/Oct 2022) → The Technology (Mar 2024)KIND Q3 FY2025 report; Incruit history; Digital Today 14 Mar 2024
Founding / incorporationConverted to a corporation as Korea Fermentation Co. in April 1987 (registered incorporation date shown as 9 May 1987). The accounting acquirer in the 2008 merger, Pharmswell Co., was founded in 1999Incruit company history; Medical Times 8 May 2008
Incorporation jurisdictionRepublic of KoreaFilings (via press)
HeadquartersNot confirmed in a current filing. The head office moved to a knowledge-industry centre in Wonju Innovation City, Gangwon Province, in May 2018. Simply Wall St lists Seoul. The March 2024 AGM was held at a shared-office venue in Gangnam-gu, SeoulEtoday 4 Jun 2018; Simply Wall St; Digital Today 14 Mar 2024
Stock exchange (historical)KOSDAQ (Korea Exchange), listed October 2001; delisted 10 August 2026Findata (DART extract); Digital Today 28 Jul 2026
Current trading venueK-OTC (Korea Financial Investment Association), Delisted Company Section, from 30 Sep 2026 for up to 6 monthsSBS Biz 28 Sep 2026
Ticker043090 (formerly 043090.KQ)KRX
ISINKR7043090000 (derived using the standard KRX ISIN structure and check digit; not confirmed against a filing)Analyst derivation
CUSIPNot applicable / not publicly disclosed—
Fiscal year end31 DecemberValueLine Korea
Employees34 (Google Finance, undated); 21 (Simply Wall St, 2025); 37 (Incruit, 2025 data). Official headcount trend not publicly disclosedAs listed
AuditorNot publicly disclosed in the sources reviewed. In May 2026 the Securities & Futures Commission imposed a 3-year designated-auditor regimeAsia Economy 6 May 2026
Shares outstandingAbout 4.14 million (after a 2026 share consolidation); 12,418,275 as of Sep 2025ValueLine (Q1 FY2026 update); Digital Today 3 Sep 2025
Market capitalisationAbout KRW 0.7bn at the last KOSDAQ liquidation-trading price (KRW 171, 7 Aug 2026). About KRW 0.43bn at the K-OTC reference price of KRW 103 (derived: 103 × ~4.14M shares)StockHub; analyst derivation
Largest shareholderPNS Industry Fund (피엔에스인더스트리펀드) and related parties, 13.42% (Sep 2025). From Nov 2025 the fund's controlling contributors are DB Investment and FastroundDigital Today 3 Sep 2025; Dealsite 5 Nov 2025
CEOPark Sung-min (박성민), per press reports in Sep 2026Sateconomy 28 Sep 2026
Websitepharmswell.com (legacy domain; it still shows the Cube&Company name). A later domain, exergy21.net, was used for merger noticesCompany site; KIND merger notice

The Technology Co., Ltd. began as a Korean fermentation company and in 2008 merged with synthetic-API maker Pharmswell. For most of its history it produced generic active pharmaceutical ingredients. Since 2019, a sequence of short-tenure controlling shareholders has used the listed shell to fund a series of unrelated diversifications: in-vitro diagnostics, fire-suppression holdings, real-estate project management, air-source heat pumps, food-waste processor distribution, second-hand IT infrastructure, mobile-game publishing and anti-drone technology. Each was accompanied by a name change and by convertible-bond or rights-issue financing.

Revenue never scaled. It peaked at KRW 16.8bn in FY2023 against an operating loss of KRW 16.0bn. Regulators later found that FY2021–FY2022 revenue had been partly fabricated. After failing KOSDAQ's revenue and quality thresholds, the company was delisted in August 2026.

Today it is best characterised as a loss-making, sub-scale domestic distributor and holding vehicle, trading over the counter, with going-concern, governance and legal risks that dominate any operating thesis.


Company's own description (paraphrased from the latest periodic report, as summarised by ValueLine Korea, Q1 FY2026 update)

The company describes itself as founded in 1987 and listed on KOSDAQ in 2001, with pharmaceutical raw-material (API) manufacturing and sales as its historical core. It says it built capability in API synthesis and production. To lift revenue and create new profit sources, it is diversifying into four reporting areas:

Distribution: it entered the food-waste processor market, framed as an ESG initiative.

Network equipment: sale of network equipment.

Games: mobile-game launches and direct publishing through alliances with game publishers.

Other: pharmaceuticals, the Exergy heat-pump business and miscellaneous activities.

Independent characterisation

On the evidence available, the business is a multi-line trading and distribution company with a residual pharmaceutical franchise, not a technology company in any substantive sense.

Revenue model: almost entirely product resale (goods distribution). This covers food-waste processors, refurbished and new network and server hardware (inherited from the 2023–2025 absorption of IT-infrastructure reseller Ainsys INC), and API sales. Service income such as IT maintenance, rental and data erasure from the Ainsys book, and game-publishing revenue appear to be minor. No subscription or licensing model has been disclosed.

Value-chain position: a downstream distributor and reseller with low gross margins. Google Finance quarterly data show cost of goods sold absorbing 74%–89% of revenue between Q2 FY2025 and Q1 FY2026, implying gross margins of roughly 11%–26%. The original Pharmswell/Co-Biotech business was an upstream API manufacturer with BGMP and KGSP-certified facilities (Incruit company profile). Whether meaningful in-house API manufacturing remains is not publicly disclosed.

Customer types: B2B in IT hardware (telecoms, cloud managed-service providers, system integrators, government agencies and global third-party-maintenance firms, per the 2023 Ainsys description). B2B2C and B2C in food-waste processors (construction companies, retail, schools, restaurants and large marts were named as target channels in 2022). B2B in APIs (domestic finished-dose pharmaceutical makers).

End-markets: Korean domestic markets only. ValueLine shows no export revenue line.

Business-model evolution (strategic "identity" by controlling shareholder)

PeriodControlling shareholderCorporate nameBusiness narrative
2008–2019Founder-era management, later Daol Pharmaceutical and related partyPharmswell BioSynthetic and fermentation API manufacturer; 2017–2019 push into in-vitro diagnostics via affiliate Cube Bio
2019–2021Cube Partners No.1 Partnership (큐브파트너스1호조합)Cube&CompanyAPI plus diagnostics (purine-metabolite analysis kit via Cube Bio)
Jul 2021–Aug 2022Hanchang Corp. (㈜한창, KOSPI)Hanju Chemical & Holdings → Hanchang BiotechAPI, 40% stake in fire-suppression maker Hanju Chemical, real-estate PM, online commerce, food-waste processor distribution, "metaverse/NFT" vision
Aug 2022–2023Jeonheung C&C (전흥씨엔씨; chairman Lee Yong-heung of World One Hi-Tech)Exergy21Air-source heat-pump distribution, smart-farm energy efficiency, IT infrastructure (Ainsys), UAV and anti-drone investments
Late 2023–Nov 2025PNS Industry Fund (contributors incl. Multo, Sight Planners, PNS The Curtain Wall)The TechnologyDistribution (food-waste processors), network equipment, mobile games
Nov 2025–presentPNS Industry Fund, now led by DB Investment and FastroundThe TechnologyDelisting litigation; investment in Xecure Hitron convertible bonds

Sources: Dealsite 14 Nov 2024; Asia Economy 15 Nov 2021, 8 Aug 2022; Energy Economic News 25 Mar 2024; Dealsite 5 Nov 2025.

Strategy

Stated strategy (paraphrased from the latest periodic report summary)

Management's stated strategy is to improve revenue and create new profit sources through diversification into four lines: distribution (food-waste processors as an ESG play), network equipment, mobile games and residual pharmaceuticals. The goal is to keep expanding the portfolio (ValueLine summary of the latest report). After the delisting decision, management's public priority was restoring listing eligibility by lifting stand-alone revenue, with profitability to be "addressed gradually" (company official, paraphrased; Dealsite 7 Jul 2025).

No investor day has been held and no medium-term targets have been published.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus / outcomeSource
Capital reduction (first attempt)Nov 20243-for-1 share consolidation to eliminate the accumulated deficitFailed: EGM lacked quorumDealsite 14 Nov 2024
Capital reduction (second attempt)Dec 2024 – Aug 202510-for-1 consolidation proposed; a reduction became effective in Aug 2025 (largest holder's stake fell by a factor of 6)Executed (final ratio as implemented not confirmed)Dealsite 4 Dec 2024; Digital Today 3 Sep 2025
BW issuance2,024KRW 12.5bn bond with warrantsCompletion not publicly disclosedDealsite 14 Nov 2024
Syswork acquisition2024 – Jul 2025Joined the ReValued Work consortium with the then-largest shareholder Multo to acquire Syswork, then in court rehabilitationTerminated Jul 2025 for lack of funds and limited effect on stand-alone revenueDealsite 7 Mar 2025, 7 Jul 2025
Ainsys absorptionDecided Jul 2023; amended Mar 2025Bring IT-hardware revenue into the stand-alone accountsCompleted 2025KIND 31 Mar 2025; Dealsite 7 Jul 2025
Delisting litigationSep 2025 – Jul 2026Injunction against the KOSDAQ delisting decisionDismissed 28 Jul 2026ChickStock (DART)
Xecure Hitron investmentOct–Nov 2025KRW 4bn purchase of Xecure Hitron CBs, joint participation in its KRW 8bn rights issue and joint purchase of a 6.55% stake, alongside SonokongCompletion not publicly disclosed; strategic rationale questioned by the pressDealsite 5 Nov 2025; Hankyung 14 Nov 2025
Further share consolidation2,026Share count cut to about 4.14M; trading halt extended pending new-share listingExecutedDatatooza 9 Apr 2026; ValueLine
K-OTC tradingSep 2026Designated to the Delisted Company Section (provides liquidity, not a relisting path)Trading from 30 Sep 2026; maximum 6 monthsSBS Biz 28 Sep 2026

ESG, cost programmes and guidance

ESG: the food-waste processor business and the Exergy heat pump were positioned as ESG and carbon-reduction initiatives. No emissions targets were set.

Cost programmes: none with quantified targets disclosed.

Guidance: none. Historical "guidance" consisted of executive statements, none of which materialised:

  • 2021: return to operating profit "next year" and revenue growth of "several tens of times" (Asia Economy 23 Nov 2021).

  • 2022: continue profitability (Asia Economy 12 May 2022).

Products & Services

The catalogue below lists every product line identified in public sources. Fields not disclosed are marked as such.

Distribution segment

Product / lineDescriptionKey capabilities (as described by company)Target customerLaunch / latest yearPricing model
MUMS (멈스) bio food-waste processorMicrobial-decomposition food-waste disposer distributed under a general-distributorship rightBiological (microbe-based) decomposition of household and commercial food wasteHousing developers, retail, schools, restaurants, large martsDistribution from late 2021/2022Not publicly disclosed (product resale)
Other traded goodsGeneral distribution——2021 onwardResale
Online commerce (legacy, 2021)Influencer × apparel/cosmetics brand collaborationsNew-media commerceConsumersAnnounced Nov 2021—

Source: Asia Economy 12 May 2022, 15 Nov 2021.

Network Equipment segment (ex-Ainsys INC)

Product / serviceDescriptionCapabilitiesCustomers (as of 2023)YearPricing
IT infrastructure hardware supplyServers, storage, network equipment for IT build-outsNew and refurbished (recycled) enterprise hardwareGovernment agencies, KT, Megazone Cloud, Naver Systems, NamutechAinsys founded 2011Resale
Equipment rentalShort/long-term rental of IT hardware—As above—Rental fees (not disclosed)
Data erasureCertified data deletion on decommissioned equipment—As above——
Equipment relocation and integrated maintenanceData-centre moves; third-party maintenance (TPM)Company said Ainsys was the only Korean firm listed in a Gartner TPM market guide; member of the Service Industry AssociationPark Place Technologies, Nordic Computer, Exeo Global, domestic clients—Service contracts (not disclosed)
"AICE security" / AI network detection and response (planned)Unsupervised-learning AI security engineNetwork detection and response—Planned 2023—

Source: Asia Economy 28 Jul 2023; Financial News 3 Apr 2023; TheVC.

Games segment

Product / serviceDescriptionPartnerYearPricing
Mobile-game publishingLaunch and direct publishing of mobile titles through alliancesPangsky (FY2023 revenue KRW 20.8bn, operating profit KRW 1.1bn, per press)2024 onwardNot disclosed; title names not publicly disclosed

Source: Energy Economic News 25 Mar 2024; ValueLine summary.

Other segment

Product / lineDescriptionCapabilitiesTarget customerYearPricing
Generic APIs (synthetic)Development, manufacture and distribution of generic APIs at BGMP/KGSP facilitiesSynthesis know-how and patents (Pharmswell); individual molecules not publicly disclosedKorean finished-dose drug makersSince 1999/2008—
Fermentation-derived APIs (legacy Co-Biotech)Fermentation technology and production equipmentFermentationPharma companiesSince 1987—
Avian-influenza treatment process (historical)Manufacturing process completed in 2005; joint R&D with Daehan New Pharm to 2010Process chemistry—2,005—
Microbial bio productsMicrobe-based bio products named as a future revenue driver——Announced Nov 2021—
Exergy21 air-source heat pumpLarge-capacity air-heat heat-pump heating/cooling/hot-water system developed by former co-CEO Lee Yong-heungNo fossil fuel. Company claimed 54%–85% heating/cooling cost savings; installed at Samsung Omni Tower (2005), KT labs and IDCs, a 5,000-pyeong mushroom farm in Gimje, and herb and paprika farmsSmart farms, large commercial buildings, data centresDistribution from Oct 2022—
Purine-metabolite analysis kit (Cube Bio, affiliate)In-vitro diagnostic kit; production plant planned in WonjuPurine metabolomicsClinics, screeningPlanned 2018–2019—
Real-estate PM (legacy)Project management for redevelopment from permitting to completionLeveraged Hanchang's experienceDevelopers2,021Contract fees (KRW 0.9bn and 1.4bn contracts)
Anti-drone (Exergy Solutions)Counter-UAV business——2,023—

Sources: Medical Times 8 May 2008; Incruit; Financial News, MT and NBN 28 Oct 2022; Etoday 4 Jun 2018; Asia Economy 15 Nov 2021, 28 Jul 2023.

Financial Narrative

Important caveats

  1. Falsified revenue. The FSC found that the company booked fictitious goods sales and cost of sales of KRW 2,374M in FY2021 and KRW 2,165M in FY2022. The transactions had no commercial substance or collectability, and the company obstructed its external audit (Metro Seoul 17 Jun 2026; Policy Briefing summary). Whether published FY2021–FY2022 figures have been restated is not publicly disclosed.

  2. Inconsistent comparatives. The FY2023 results release stated revenue growth of +330.2%, operating-loss growth of +216.6% and net-loss growth of +680% (Edaily, Mar 2024). These ratios do not reconcile with the FY2022 figures originally published (revenue KRW 3,874M; operating loss KRW 3,887M; net profit KRW 4,730M; Edaily, Mar 2023). This implies the FY2022 comparatives were restated or reclassified, possibly for discontinued operations linked to the Hanju Chemical disposal. The restated FY2022 figures are not publicly disclosed.

  3. FY2021 revenue is derived. It is back-calculated from the reported −56.21% FY2022 decline: 3,874 / (1 − 0.5621) ≈ 8,847.

  4. Balance-sheet, cash-flow, EPS and ratio data beyond those listed are not publicly disclosed in accessible sources.

Income statement

Sources: FY2022 — Edaily (Mar 2023). FY2023 — Edaily (Mar 2024). FY2024 — Digital Today 3 Sep 2025 and 25 Sep 2025. FY2025 — Digital Today 28 Jul 2026. FY2021 — derived. Dividends: no dividend was reported in any source reviewed, and accumulated deficits would legally prevent one; recorded as zero.

Earlier reference points:

FY2020 (Cube&Company): revenue ≈KRW 5,200M and operating loss ≈KRW 3,600M, as cited by the CEO at the Nov 2021 EGM (Asia Economy 23 Nov 2021).

FY2007 (Pharmswell stand-alone): revenue KRW 24,100M, operating profit KRW 3,200M (Medical Times 8 May 2008).

Growth

  • FY2023 growth is computed against the originally published FY2022 revenue; the company reported +330.2%.

Revenue CAGR FY2022–FY2025: about +48.2% a year on reported figures. This is inflated by the low, partly fabricated FY2022 base.

Revenue CAGR FY2021–FY2025: about +9.2% a year (derived FY2021 base).

  • On a basis that excludes fabricated sales, the FY2021 to FY2025 change is roughly +18% a year. This is an analyst derivation and assumes the reported FY2021 figure was not already restated.

Balance sheet

Sources: Digital Today 3 Sep 2025 (FY2024); Digital Today 28 Jul 2026 (FY2025).

Additional disclosed balance-sheet data points:

Cash and short-term financial instruments: KRW 13.3bn at 31 Mar 2023 (Dealsite 2 Aug 2023).

Unredeemed CBs: KRW 26.4bn across series 17, 18, 20 and 21 at Aug 2023 (Dealsite 2 Aug 2023).

Hanju Chemical sale receivable: KRW 23bn balance, deferred to 31 Jan 2024 (Dealsite 2 Aug 2023). Collection status is not publicly disclosed.

BW issuance decided: KRW 12.5bn bond with warrants approved in 2024 (Dealsite 14 Nov 2024). Completion status is not publicly disclosed.

Implied equity, end-2019: ≈KRW 26bn (derived: a KRW 2.71bn CB resale equalled 10.42% of equity; Etoday 26 Jun 2020).

Cash flow

ValueLine Korea publishes a cash-flow line, but the values extracted were not interpretable with confidence, so they are excluded under the no-fabrication rule.

Ratios (computed on year-end balances where available)

Aggregator cross-checks: ValueLine shows trailing ROE of −76.49% at the Q1 FY2026 update; StockHub shows −80.17%.

Quarterly and trailing data (aggregators)

Source: Google Finance (S&P data). These quarterly operating figures do not fully reconcile with the reported FY2025 operating loss of KRW 3.2bn. Q2–Q4 alone sum to −KRW 5.0bn, which would imply a positive Q1 FY2025. Treat them as indicative only.

Source: ValueLine Korea (consolidated, Q1 FY2026 update).

Commentary on trends, inflections and drivers

Structural decline of the core. In 2007, Pharmswell alone generated KRW 24.1bn of revenue at a 13% operating margin. By FY2020 the renamed Cube&Company reported about KRW 5.2bn of revenue and a KRW 3.6bn operating loss. The API franchise appears to have eroded through the late 2010s while management attention and capital went to diagnostics (Cube Bio) and the Wonju relocation. Every subsequent "new business" was layered on a shrinking core.

FY2021–FY2022: revenue of questionable quality. Revenue in these years mixed real but small new lines (PM fees, early MUMS distribution) with fictitious goods-trading sales later identified by the FSC. Fabricated sales were about 27% of derived FY2021 revenue and 56% of reported FY2022 revenue. FY2022's reported net profit of KRW 4.7bn was not operational: it came from the Hanju Chemical stake (equity income, then a disposal for KRW 25bn), while operating losses persisted at about KRW 3.9bn.

FY2023: inflection in scale, not economics. Revenue rose to KRW 16.8bn, mainly by consolidating the Ainsys IT-hardware business (about KRW 19.6bn revenue on its own in FY2022). Operating loss widened to KRW 16.0bn and net loss to KRW 26.2bn. Management blamed rate rises and inflation (Edaily, Mar 2024). In practice, the loss reflects low-margin hardware resale, heavy SG&A, and probable write-downs of the investment portfolio (Katus, CB-funded ventures) and of the heat-pump business. The breakdown is not publicly disclosed.

FY2024: contraction. Consolidated revenue fell 38% to KRW 10.4bn. Stand-alone revenue fell 53% to KRW 2.3bn, below the KOSDAQ KRW 3bn threshold, which triggered the listing review. Operating loss narrowed to KRW 7.2bn but net loss stayed high at KRW 18.4bn. Equity of KRW 30.7bn masked a large accumulated deficit, which the failed and then re-attempted capital reductions were designed to eliminate.

FY2025: smaller losses, shrinking balance sheet. Revenue recovered to KRW 12.6bn as the Ainsys absorption moved hardware sales into the stand-alone entity, and operating loss narrowed to KRW 3.2bn. Net loss of KRW 14.3bn was again far larger than the operating loss, pointing to continued financial-asset write-downs or valuation losses. Total assets more than halved from KRW 43.3bn to KRW 20.0bn and equity fell from KRW 30.7bn to KRW 16.0bn in one year: a rapid consumption of the capital base.

Q1 FY2026. Revenue of about KRW 4.4bn was the best quarter in the aggregator series, but the company still lost about KRW 0.6bn at the operating line on gross margins of roughly 15%. On TTM data, net losses are narrowing (−KRW 11.75bn at March 2026) but remain about 80% of revenue.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsProducts / services

Distribution (유통사업부문)

Food-waste processing business and general goods distribution

Food-waste processors (the MUMS brand was distributed under exclusive rights from 2022) and other traded goods

Network Equipment (네트워크장비사업부문)

IT-infrastructure hardware business absorbed from Ainsys INC

Servers, storage and network equipment; historically also rental, data erasure, relocation and third-party maintenance

Games (게임사업부문)

Mobile-game publishing

Mobile-game launches and publishing under alliances (Pangsky CB investment in 2024)

Other (기타사업부문)

Legacy and residual activities

Pharmaceuticals/APIs, the Exergy air-source heat pump, other

Segment revenue (KRW Mn)

Segment revenue (KRW Mn)FY2023FY2024FY2025

Total consolidated revenue

16,76210,40012,600

Segment operating profit (KRW Mn)

Segment operating profit (KRW Mn)FY2023FY2024FY2025

Total consolidated operating profit

-16,006-7,200-3,200

Group Entities

EntityRelationshipBusinessStatusSource

The Tech D&R (㈜더테크디엔알)

Consolidated subsidiary

—

Active per Q3 FY2025 report

KIND Q3 FY2025

Exergy Solutions (엑서지솔루션스)

Subsidiary

Anti-drone business

Status not publicly disclosed

Asia Economy 28 Jul 2023

Ainsys INC (아인시스아이엔씨)

Former 100% subsidiary, absorbed

IT infrastructure hardware, TPM

Absorbed; recorded as closed Jun 2025

KIND 31 Mar 2025; TheVC

Hanju Chemical (한주케미칼)

Former 40% associate

Gas-type fire suppression

Sold back to Hanchang (KRW 25bn)

Dealsite 2 Aug 2023

Cube Bio (큐브바이오)

Former affiliate

In-vitro diagnostics (purine-metabolite analysis kit)

Relationship status not publicly disclosed

Etoday 2018–2019

Katus (카투스)

Equity investee (KRW 6bn, May 2023)

UAV

Status not publicly disclosed

Dealsite 2 Aug 2023

Pangsky (팡스카이)

CB investee (2024)

PC/mobile game publishing

Status not publicly disclosed

Energy Economic News 25 Mar 2024

“—” = not publicly disclosed.

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

8,8473,87416,76210,40012,600

Of which fabricated revenue found by FSC (KRW Mn)

2,3742,165———

Revenue excl. fabricated sales, analyst-derived (KRW Mn)

6,4731,70916,76210,40012,600

Operating income (KRW Mn)

—-3,887-16,006-7,200-3,200

Net income (KRW Mn)

—4,730-26,169-18,400-14,300

Dividends per share (KRW)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Operating margin (%)

-100.3-95.5-69.2-25.4

Net margin (%)

122.1-156.1-176.9-113.5

Margin Analysis (%) — Revenue YoY growth

MetricFY2022FY2023FY2024FY2025

Revenue YoY growth (%)

-56.2332.7-38.021.2

Balance Sheet

MetricFY2024FY2025

Total assets (KRW Mn)

43,30020,000

Total liabilities (KRW Mn)

12,6003,900

Total equity (KRW Mn)

30,70016,000

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW Mn)

00000

Margin Analysis (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (%)

-59.9-89.4

ROA (%)

-42.5-71.5

Liabilities to equity (%)

41.024.4

Asset turnover (x)

0.240.63

Equity to assets (%)

70.980.0

Income Statement (Quarterly)

Metric (KRW Mn)Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026

Revenue

2,4401,7506,3804,370

Cost of goods sold

1,6201,2905,6903,710

SG&A

1,3509958731,090

Operating income

-3,930-873-207-593

Pre-tax income incl. unusual items

-5,210-785-5,900338

Income Statement (KRW)

Trailing-12-month metric (KRW 100M)Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026

TTM revenue

99.298.987.1125.7149.6

TTM net income

-170.7-198.0-152.9-143.0-117.5

Region revenue (KRW Mn)

Region revenue (KRW Mn)FY2023FY2024FY2025

South Korea

16,76210,40012,600

Capital Markets

ItemDetailSource

KOSDAQ listing

Oct 2001 – 10 Aug 2026

Findata; Digital Today

Current venue

K-OTC Delisted Company Section from 30 Sep 2026, for up to 6 months; reference price KRW 103; daily limit ±30%

SBS Biz; Bizwatch 28 Sep 2026

Par value

KRW 500

Dealsite 14 Nov 2024

Share Price History

DatePrice (KRW)ContextSource

9 Aug 2022

5,280

Intraday high after the change-of-control news

Dealsite 2 Aug 2023

27 Jul 2023

535

Intraday low, down about 90% from the peak

Dealsite 2 Aug 2023

1 Aug 2023

701

Close

Dealsite 2 Aug 2023

13 Nov 2024

334

Close, 33% below par

Dealsite 14 Nov 2024

2025 (suspension)

380

Last price before the trading halt (post-Aug 2025 reduction basis)

Digital Today 3 Sep and 25 Sep 2025

Jul 2026 (pre-liquidation, consolidated basis)

1,140

380 adjusted for the 2026 3-for-1 consolidation (derived from StockHub 52-week high)

StockHub; analyst derivation

30 Jul 2026

228

First liquidation-trading day, −80%

ValueLine

7 Aug 2026

171

Liquidation trading (intraday, −18.57%)

StockHub

30 Sep 2026

103

K-OTC reference price

Bizwatch 28 Sep 2026

Share Price & Returns

PeriodReturnBasisSource

1-year (to May 2025)

-85.5%

Simply Wall St

Simply Wall St

1-year (to 30 Sep 2026)

about -91% (1,140 adjusted → 103)

Analyst derivation

Derived

3-year (Aug 2023 → Sep 2026)

below -99% after cumulative consolidations

Analyst derivation; exact figure depends on consolidation ratios not fully confirmed

Derived

5-year

below -99%

As above

Derived

Market Valuation

MetricFY2024FY2025FY2026

Market cap (KRW Mn)

11,9004,700426

Valuation Snapshot

MultipleValueSource

P/E

Negative (−0.08x on ValueLine, 30 Jul 2026)

ValueLine

P/B

0.06x (ValueLine, 30 Jul 2026); 0.03x (StockHub, 7 Aug 2026)

ValueLine; StockHub

EV/EBITDA

Not meaningful (negative EBITDA; EBITDA not disclosed)

—

EV/Sales

About 0.03x (derived from a KRW 0.43bn market cap on FY2025 revenue of KRW 12.6bn, before net cash/debt, which is not disclosed)

Derived

Peer multiples

Not compiled

—

Analyst Conclusions

Management guidance and consensus

There is no management guidance and no consensus. The only forward-looking statements on record are the 2021–2022 promises of turnaround, which did not materialise, and the 2025 commitment to expand stand-alone revenue to preserve the listing, which failed.

Bull case

  1. Operating losses are shrinking. Operating loss narrowed from −KRW 16.0bn (FY2023) to −KRW 3.2bn (FY2025), and Q1 FY2026 revenue (about KRW 4.4bn) annualises to roughly KRW 17bn. If the hardware and distribution lines hold 15%–20% gross margins and overhead is cut, operating breakeven is conceivable.

  2. The market is pricing the equity near zero against KRW 16.0bn of book equity. At the KRW 103 K-OTC reference price (P/B well below 0.1x), any credible recapitalisation, asset sale or realisation of the Xecure Hitron or other investments could re-rate the shares.

  3. New controllers may have an agenda for the shell. The November 2025 shift to DB Investment and Fastround and the Xecure Hitron transactions indicate active capital deployment. A recapitalisation or K-OTC "registered" status could provide an orderly path for remaining holders.

Bear case

  1. The listing is gone and the funding model is broken. Since 2019 the company has financed losses mainly through CBs, BWs and third-party rights issues sold into a KOSDAQ-listed stock. As a delisted K-OTC name with a six-month designation window, that channel is effectively closed while losses continue (FY2025 net loss KRW 14.3bn).

  2. Book value is eroding faster than it can be defended. Equity fell 48% in FY2025 alone. Net losses repeatedly exceed operating losses, consistent with write-downs of investments, so the remaining KRW 16bn may be similarly impaired.

  3. Legal and governance overhang. Prosecutorial referral, a three-year designated auditor, a confirmed history of fabricated revenue and audit obstruction, and six or more control changes make outside capital and customer trust hard to attract. Any further adverse audit opinion would compound this.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhy it matters
K-OTC Delisted Company Section expiryAbout 6 months after 30 Sep 2026 (≈ end-Mar 2027)Decides whether organised trading continues
KOFIA decision on re-designation to the K-OTC registered/designated sectionsAt expiryOngoing liquidity
FY2026 annual report and audit opinion (designated auditor)~Mar 2027Going-concern assessment; test of the new audit regime
Prosecutorial outcome on the SFC referralNot scheduledPotential criminal liability; damages claims
Status of Xecure Hitron CB, rights-issue and block positionsPending disclosureAsset value or loss
Further capital raising or control changes by DB Investment / FastroundUnknownRecapitalisation versus wind-down
Quarterly gross margin and operating loss trendQuarterlyWhether the operating improvement is sustainable
Minority-shareholder litigationUnknownContingent liabilities

Analyst verdict

Cube&Company — today The Technology Co., Ltd. — is a case study of how a small but once-genuine Korean pharmaceutical-ingredients manufacturer can be turned into a vehicle for successive capital-markets strategies. In 2007 its predecessor earned a 13% operating margin on KRW 24bn of API revenue. By 2020 the core had shrunk to about KRW 5bn of loss-making sales.

Each controller from 2019 onward introduced a new narrative, a new name and new mezzanine financing:

  • diagnostics;

  • a fire-suppression holding;

  • real-estate project management;

  • heat pumps and smart farms;

  • second-hand servers;

  • mobile games;

  • anti-drone technology.

None of these produced durable, profitable scale. Regulators have since established that FY2021–FY2022 revenue was partly fictitious, and that the company obstructed its auditor.

The FY2025 numbers show some operational stabilisation: consolidated revenue of KRW 12.6bn and an operating loss narrowed to KRW 3.2bn. But they are undercut by a KRW 14.3bn net loss and a halving of equity within one year. More fundamentally, the delisting on 10 August 2026 removed the listed currency on which the entire post-2019 model depended.

The K-OTC designation provides a temporary exit window for minority holders; it does not resolve the underlying problems. The KRW 103 reference price, which values the company at well under 0.1x book, is the market's verdict that reported equity is not recoverable by outside shareholders.

For institutional purposes the company is uninvestable. The legal, governance and going-concern risks are not compensated by any identifiable franchise value. The residual analytical interest lies in three questions: whether the new controllers, DB Investment and Fastround, recapitalise or extract the remaining assets; what the designated auditor concludes on FY2026; and how the prosecutorial referral resolves. Counterparties extending trade credit or entering distribution agreements should apply heightened due diligence and secure payment terms.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesAge

Park Sung-min (박성민)

CEO

In office by Sep 2026; start date not publicly disclosed

——

Jeon Young-mo (전영모)

CEO (appointed 25 Sep 2025); current status not confirmed

From Sep 2025

Director, Stefano Equity (unlisted), Jan 2022 – Jun 2025

Born 4 Jul 1968

“—” = not publicly disclosed.

Board & Management Changes

PeriodCEO / key directorContextSource
2008

Kwon Young-jin (Pharmswell CEO)

Became CEO of the merged Pharmswell Bio; Simply Wall St still lists him (stale data)

Medical Times 8 May 2008; Simply Wall St

2018

Choo Yeon-woo

CEO during the Wonju relocation and Cube Bio build-out

Etoday 4 Jun 2018

to Oct 2019

Park Kang-kyu

Resigned for personal reasons

Hankyung 24 Oct 2019

Oct 2019

Jung Jae-heon

Appointed at the Cube&Company rename

Hankyung / Newspim 24 Oct 2019

2020–2023

Lee Ji-sun (inside director, management support)

Previously at Namsung, Pharmswell Bio/Cube Bio, Hansol Secure; term Mar 2020 – Mar 2023

Findata DART extract

2021

Choi Seung-hwan

CEO under Hanchang ownership

Asia Economy 23 Nov 2021

Sep 2022

Lee Yong-heung (co-CEO)

Chairman of World One Hi-Tech and Jeonheung C&C; developer of the Exergy21 heat pump

Financial News 28 Oct 2022

Mar 2023

Choi Chang-geun (inside director; CEO of Ainsys INC); Hong Soon-ho (inside director; CPA, Shinhan Accounting)

Appointed at the FY2022 AGM

Financial News 3 Apr 2023

to Sep 2025

Oh Jong-bong

Resigned as CEO for personal reasons

Digital Today 25 Sep 2025

Sep 2025

Jeon Young-mo

Appointed CEO

Digital Today 25 Sep 2025

by Sep 2026

Park Sung-min

CEO at the time of the K-OTC designation

Sateconomy 28 Sep 2026

Major Shareholders

HolderSharesStake (%)DateSource

PNS Industry Fund (피엔에스인더스트리펀드) and related parties

1,666,666 (post Aug 2025 reduction)

13.42

3 Sep 2025

Digital Today 3 Sep 2025

Same holder, prior report

10,000,00014.47

29 Dec 2023

Digital Today 3 Sep 2025

Same holder, implied after the 2026 consolidation

≈555,555 (derived assuming a 3-for-1 consolidation)

≈13.4 (derived)

2026

Analyst derivation from ValueLine share count

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning

Distribution (food-waste processors)

Smartcara (스마트카라)

Specialist appliance brand

Established brand vs. the company's reseller role

Distribution

SK Magic (SK매직)

Large home-appliance company

Scale, rental model and channel reach far exceed the company

Distribution

Cuckoo (쿠쿠)

Large appliance group

Brand and distribution advantages

Network equipment / IT hardware and TPM

Park Place Technologies

Global TPM leader (also a historical Ainsys customer)

Global scale; partner-competitor

Network equipment

Syswork (시스웍)

Korean network-equipment firm (target abandoned in 2025)

Comparable domestic niche

Network equipment

Insung Information (인성정보)

Network-infrastructure distributor

Larger domestic distributor

Games

Pangsky (팡스카이)

Game publisher (investee/partner)

Larger than the company's games unit (FY2023 revenue KRW 20.8bn)

APIs (Other)

Kyongbo Pharm (경보제약)

Korean API maker

Larger, focused API producer

APIs

Kukjeon Pharmaceutical (국전약품)

Korean API maker

Focused competitor

APIs

Estech Pharma (에스텍파마)

Korean API maker

Focused competitor

APIs

Hwail Pharm (화일약품)

Korean API maker / distributor

Focused competitor

Competitor Detail

MetricThe Technology FY2025

Revenue (KRW Mn)

12,600

Revenue growth (%)

21.2

Operating margin (%)

-25.4

Company Snapshot

$8.9M

Revenue

34

Employees

1987

Founded

SWOT Analysis

Strengths

  • Revenue partially rebuilt: consolidated revenue rose 21.2% to KRW 12.6bn in FY2025, and Q1 FY2026 revenue of about KRW 4.37bn was the highest quarter in the aggregator series (Digital Today 28 Jul 2026; Google Finance).
  • Narrowing operating losses: operating loss improved from −KRW 16.0bn (FY2023) to −KRW 7.2bn (FY2024) to −KRW 3.2bn (FY2025).
  • Low reported leverage: liabilities of KRW 3.9bn against equity of KRW 16.0bn at FY2025 (liabilities-to-equity about 24%) (Digital Today 28 Jul 2026).
  • Inherited enterprise customer base: the Ainsys book included KT, Megazone Cloud, Naver Systems and global TPM firms (Asia Economy 28 Jul 2023).
  • Distribution rights in a growth category: the MUMS food-waste processor distributorship in a market that industry sources expected to grow from about KRW 200bn (2021) towards about KRW 1tn (Asia Economy 12 May 2022).
  • Continued disclosure discipline post-delisting: the half-year report was filed on 14 Aug 2026, which qualified the company for K-OTC designation (Sateconomy; KOFIA).

Weaknesses

  • Persistent losses: net losses of KRW 26.2bn (FY2023), KRW 18.4bn (FY2024) and KRW 14.3bn (FY2025).
  • Rapid capital erosion: total assets fell from KRW 43.3bn to KRW 20.0bn and equity from KRW 30.7bn to KRW 16.0bn in FY2025.
  • Thin gross margins: COGS was 74%–89% of revenue in Q2 FY2025–Q1 FY2026 (Google Finance).
  • Regulator-confirmed fabricated revenue: KRW 2.37bn (FY2021) and KRW 2.17bn (FY2022), plus audit obstruction (FSC, Jun 2026).
  • Ownership instability: six or more control changes since 2019 and seven corporate names (Dealsite 14 Nov 2024; KIND).
  • Failed corporate actions: the 3-for-1 reduction failed for lack of quorum (Nov 2024) and the Syswork acquisition was abandoned (Jul 2025).

Opportunities

  • K-OTC liquidity window: six months of organised trading from 30 Sep 2026, and KOFIA may move the company to its regular registered/designated sections if suitable (SBS Biz 28 Sep 2026).
  • IT-hardware refurbishment and TPM demand: cost pressure on Korean data centres and cloud MSPs, where the Ainsys capabilities are relevant (Asia Economy 28 Jul 2023).
  • Food-waste processor penetration: penetration of about 1% in 2022 leaves headroom (Asia Economy 12 May 2022).
  • Potential value in the Xecure Hitron position: if the CB, rights-issue and block purchases closed (unconfirmed), the company holds an interest in a KOSPI-listed entity (Hankyung 14 Nov 2025).
  • Cleaner capital structure after consolidations: repeated reductions in 2025–2026 reduced the accumulated deficit (Digital Today 3 Sep 2025; Datatooza 9 Apr 2026).
  • New controlling investors (DB Investment and Fastround) could recapitalise: control changed in Nov 2025 (Dealsite 5 Nov 2025).

Threats

  • Loss of listing: KOSDAQ access is gone; K-OTC designation lapses after six months (around end-March 2027) unless KOFIA re-designates (SBS Biz 28 Sep 2026).
  • Criminal and prosecutorial exposure: the company and former management were referred to prosecutors (SFC, 6 May 2026).
  • Designated-auditor regime for three years: higher audit costs and scrutiny, and a risk of non-clean opinions (SFC, May 2026).
  • Funding cliff: CB and BW markets are effectively closed to delisted issuers; historical funding relied on mezzanine instruments (Dealsite 2 Aug 2023).
  • Minority-shareholder litigation risk following the roughly 80% liquidation-trading collapse and the falsified accounts (ValueLine; FSC).
  • Competitive pressure from large appliance and IT vendors in every segment.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jun 2025Ainsys INC recorded as closed following absorption TheVCIT-hardware revenue now sits in the stand-alone entity
~Jul 2025Designated for substantive listing-eligibility review for failing KOSDAQ revenue requirements Dealsite 7 Jul 2025Start of the delisting path
Early Jul 2025Terminated the conditional investment agreement for the Syswork acquisition Dealsite 7 Jul 2025Strategic retreat; funding constraints
Jul 2025Management stated its focus on stand-alone revenue expansion via the merger Dealsite 7 Jul 2025Profitability deprioritised
27 Aug 2025Capital reduction took effect Digital Today 3 Sep 2025Clears part of the deficit; share count cut
3 Sep 2025PNS Industry Fund reported 1,666,666 shares (13.42%) Digital Today 3 Sep 2025Control stake confirmed post-reduction
5 Sep 2025KOSDAQ Market Committee decided on delisting ChickStock (DART)Decisive negative event
8 Sep 2025Filed an injunction to suspend the delisting decision ChickStock; Topstar NewsDelisting procedures (liquidation trading) put on hold
25 Sep 2025CEO Oh Jong-bong resigned; Jeon Young-mo appointed Digital Today 25 Sep 2025Leadership turnover
30 Oct 2025Bought KRW 4bn of Xecure Hitron CBs off-exchange (alongside Sonokong) Hankyung 14 Nov 2025Capital deployed into another listed company while delisting was pending
4 Nov 2025PNS Industry Fund's largest contributors changed to DB Investment and Fastround Dealsite 5 Nov 2025De facto change of control
Nov 2025Replaced the original subscriber in Xecure Hitron's third-party rights issue (cut from KRW 10bn to 8bn) and jointly acquired 6.55% from the prior largest holder Hankyung 14 Nov 2025Potential new control position in a KOSPI company; completion unconfirmed
14 Nov 2025Q3 FY2025 quarterly report filed (four segments) KINDLatest segment definitions
12–19 Feb 2026FSC delisting reform and KRX "rapid exit" plan: improvement periods cut to 1 year; KOSDAQ thresholds of KRW 15bn market cap or KRW 3bn revenue from 2026 Bizwatch 19 Feb 2026; Bizhankook 10 Feb 2026Regulatory environment hardens
~Mar 2026FY2025 results: revenue KRW 12.6bn; operating loss KRW 3.2bn; net loss KRW 14.3bn; equity KRW 16.0bn Digital Today 28 Jul 2026Losses narrow; balance sheet halves
9 Apr 2026Trading-halt period extended to cover both the court decision and new-share listing after a capital reduction Datatooza 9 Apr 2026Second share consolidation
~May 2026Q1 FY2026 revenue ≈KRW 4.37bn; operating loss ≈KRW 0.59bn Google FinanceBest quarterly revenue in the series
6 May 2026SFC: 3-year designated auditor; company and former executives referred to prosecutors for FY2021–FY2022 fictitious sales Asia Economy 6 May 2026Legal and reputational damage
~May 2026Disclosed that the SFC action created an additional ground for substantive review Topstar NewsCompounds the delisting case
17 Jun 2026FSC finalised penalties: KRW 289.8M on the company, KRW 21.8M on former executives, plus a KRW 48M fine and a recommendation to dismiss the former officer in charge Metro Seoul 17 Jun 2026Cash and legal cost
28 Jul 2026Seoul Southern District Court dismissed the injunction; KRX lifted the halt and scheduled liquidation trading ChickStock; Digital Today 28 Jul 2026Delisting confirmed
30 Jul 2026Liquidation trading began; price fell about 80% to KRW 228 ValueLineValue destruction for minority holders
7 Aug 2026Liquidation trading ended (intraday KRW 171) StockHubFinal KOSDAQ trades
10 Aug 2026Delisted from KOSDAQ Digital Today 28 Jul 2026End of listed status after about 25 years
14 Aug 2026Half-year FY2026 report filed despite delisting Sateconomy 28 Sep 2026Continued disclosure (used for K-OTC eligibility)
28 Sep 2026KOFIA designated the shares to the K-OTC Delisted Company Section (124 companies tradable on K-OTC) SBS Biz; MT 28 Sep 2026Liquidity window for holders
30 Sep 2026K-OTC trading began at a reference price of KRW 103 (±30% daily limit) Bizwatch 28 Sep 2026Price discovery off-exchange

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total consolidated revenue fell from KRW 16,762 Mn in FY2023 to KRW 12,600 Mn in FY2025.
Cube&Company Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total consolidated revenue16,76210,40012,600

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. KIND (KRX) — Q3 FY2025 quarterly report extract (14 Nov 2025)
  2. KIND (KRX) — Correction to merger decision (31 Mar 2025)
  3. SBS Biz — K-OTC designation (28 Sep 2026)
  4. Bizwatch — K-OTC designation and delisting chronology (28 Sep 2026)
  5. Sateconomy — K-OTC and delisting analysis (28 Sep 2026)
  6. Money Today — K-OTC designation (28 Sep 2026)
  7. Herald Business — delisting for revenue shortfall (Sep 2026)
  8. Financial News — K-OTC (28 Sep 2026)
  9. Digital Today — liquidation trading and FY2025 figures (28 Jul 2026)
  10. ChickStock — DART summary of injunction dismissal (28 Jul 2026)
  11. Topstar News — additional substantive-review ground (2026)
  12. Datatooza — trading-halt extension (9 Apr 2026)
  13. Metro Seoul — FSC sanctions detail (17 Jun 2026)
  14. Asia Economy — FSC penalties (17 Jun 2026)
  15. Asia Economy — SFC auditor designation (6 May 2026)
  16. Policy Briefing summary via Dazabi (Jun 2026)
  17. Bizwatch — KRX 2026 rapid-exit plan (19 Feb 2026)
  18. Bizhankook — KOSDAQ delisting statistics (10 Feb 2026)
  19. Hankyung — Xecure Hitron transactions (14 Nov 2025)
  20. Dealsite — de facto control change and CB investment (5 Nov 2025)
  21. Digital Today — CEO change (25 Sep 2025)
  22. Digital Today — PNS stake report and FY2024 figures (3 Sep 2025)
  23. Dealsite — Syswork acquisition withdrawn (7 Jul 2025)
  24. Dealsite — revenue and market-cap collapse (7 Mar 2025)
  25. Dealsite — second capital-reduction attempt (4 Dec 2024)
  26. Dealsite — failed capital reduction and ownership history (14 Nov 2024)
  27. Energy Economic News — PNS takeover and Pangsky investment (25 Mar 2024)
  28. Edaily — rename to The Technology (29 Mar 2024)
  29. Digital Today — 2024 AGM agenda and name history (14 Mar 2024)
  30. Edaily — FY2023 results
  31. Edaily — FY2022 results
  32. Dealsite — CB put-option risk and Hanju Chemical sale (2 Aug 2023)
  33. Asia Economy — Ainsys absorption merger (28 Jul 2023)
  34. Financial News — 2023 director appointments (3 Apr 2023)
  35. Financial News — Exergy21 rename (28 Oct 2022)
  36. Money Today — Exergy21 rename (28 Oct 2022)
  37. MTN — change of control to Jeonheung C&C (10 Aug 2022)
  38. Asia Economy — Jeonheung C&C acquisition (8 Aug 2022)
  39. Asia Economy — Q1 FY2022 results and MUMS (12 May 2022)
  40. Asia Economy — Hanchang Biotech rename completed (8 Dec 2021)
  41. Asia Economy — EGM for Hanchang Biotech rename (23 Nov 2021)
  42. Asia Economy — PM and commerce businesses (15 Nov 2021)
  43. Etoday — CB resale (26 Jun 2020)
  44. Hankyung — Cube&Company rename (24 Oct 2019)
  45. Newspim — Cube&Company rename (24 Oct 2019)
  46. Findata — DART extract incl. name history (May 2021)
  47. Etoday — Cube Bio UICC partnership (22 Jul 2019)
  48. Etoday — HQ relocation to Wonju (4 Jun 2018)
  49. Medical Times — Co-Biotech/Pharmswell merger (8 May 2008)
  50. Incruit — company profile and early history
  51. TheVC — Ainsys INC profile
  52. Google Finance — 043090 quarterly data
  53. Simply Wall St — company profile
  54. ValueLine Korea — financial summary, income and cash flow
  55. StockHub — liquidation-trading data

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.